Neoadjuvant Pembrolizumab Plus Chemo Treats Early TNBC
THURSDAY, Feb. 10, 2022 -- For patients with previously untreated stage II or III triple-negative breast cancer, the rate of event-free survival is higher for those receiving neoadjuvant pembrolizumab combined with chemotherapy versus neoadjuvant...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pharmaceuticals